ARTICLE | Clinical News

NLG919: Phase Ia data

October 5, 2015 7:00 AM UTC

Data from 19 patients with recurrent or advanced solid tumors in an open-label, U.S. Phase Ia trial showed that twice-daily doses of up to 800 mg oral GDC-0919 for 21 days of a 28-day cycle were well ...